Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.116 EUR | -2.45% |
|
-5.74% | -68.61% |
06-28 | AB Science: negative CHMP opinion for masitinib in ALS | CF |
06-03 | AB Science: share price falls on resumption of trading | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-68.61% | 72.42M | |
+7.39% | 72.4B | |
+15.93% | 8.98B | |
+17.59% | 4.28B | |
-22.81% | 4.28B | |
+25.93% | 4.01B | |
+4.64% | 2.16B | |
+9.09% | 1.95B | |
-36.86% | 1.9B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- AB Stock
- News AB Science
- AB Science Expects European Marketing Authorization for Rare Neurological Disease Drug in Early 2024